Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
oFCG in Newly Diagnosed CLL/SLL
NCT05322733Phase 2Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Apr 2022
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of orelabrutinib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Bone Marrow Undetectable Minimal Residual Disease Rate. Status: unknown.
02
Drugs
orelabrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT05322733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05322733.